

WILLS EYE PUBLICATIONS LIST – NOVEMBER 2024

**A Wills Eye affiliation search function was used in PubMed to populate the list below. Any manuscripts published in November 2024 under a different affiliation and/or not present on PubMed was not included in this list.*

1. Treatment patterns of childhood glaucoma in the United States: Analysis of IRIS® Registry (Intelligent Research in Sight). Fujita A, Vu DM, Aziz K, Chang TC, Chung IY, Ciociola EC, Friedman DS, Lokhande A, Lorch AC, Miller JW, Parikh P, Rothman AL, Seresirikachorn K, Elze T, Zebardast N, Pershing S, **Hyman L, Haller JA**, Lee AY, Lee CS, Lum F, Miller JW, Lorch A; IRIS® Registry Analytic Center Consortium. Am J Ophthalmol. 2024 Nov 29:S0002-9394(24)00550-6. doi: 10.1016/j.ajo.2024.11.020. Online ahead of print. PMID: 39617117
2. Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial-24-week Outcomes of Uveitic Macular Edema Retreatment. Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee; Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, **Dunn JP**, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Ophthalmology. 2024 Nov 27:S0161-6420(24)00746-2. doi: 10.1016/j.ophtha.2024.11.021. Online ahead of print. PMID: 39612949
3. Refillable Drug Reservoirs for Retinal Vascular Diseases. Clark AJ, **Regillo C**, Gune S, Pieramici DJ. Am J Ophthalmol. 2024 Nov 26:S0002-9394(24)00541-5. doi: 10.1016/j.ajo.2024.11.009. Online ahead of print. PMID: 39608741
4. Semiautomated measures of foveal immaturity from handheld swept-source optical coherence tomography are associated with retinopathy of prematurity severity. Tam EK, **Lee KE**, Lawson SE, Monger TR, Legocki AT, Kelly JP, Liu T, Zheng Y, Ding L, Tarczy-Hornoch K, Wang R, Cabrera MT. Br J Ophthalmol. 2024 Nov 27:bjo-2023-324220. doi: 10.1136/bjo-2023-324220. Online ahead of print. PMID: 39603717
5. Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research. Dalvin LA, Andrews-Pfannkoch CM, Miley DR, Hogenson TL, Erickson SA, Malpotra S, Anderson KJ, Omer ME, Almada LL, Zhang C, Li H, Salomao DR, **Shields CL, Lally SE**, Malsch RM, Armitage JA, Holmes HL, Romero MF, Fautsch MP, Markovic SN, Fernandez-Zapico ME. Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):60. doi: 10.1167/iovs.65.13.60. PMID: 39601636 **Free PMC article.**
6. Interventional Glaucoma: Improving the Patient-Provider Educational Exchange. **Katz LJ, Myers JS**, Herndon LW, Kresch YS, Hengerer FH. Clin Ophthalmol. 2024 Nov 21;18:3365-3374. doi: 10.2147/OPTH.S491287. eCollection 2024. PMID: 39588379 **Free PMC article.**

7. Non-Conditional and Conditional Metastasis of Uveal Melanoma Per Millimeter-By-Millimeter in Thickness in 8034 Patients. **Sener H, Bansal R, Catapano T, Shields JA, Shields CL.**Semin Ophthalmol. 2024 Nov 24:1-8. doi: 10.1080/08820538.2024.2432907. Online ahead of print.PMID: 39580712
8. Real-World Functional Outcomes and Quality of Life in Geographic Atrophy. Borkar D, Rahimy E, **Khan MA, Ho AC**, Hatfield M, Nguyen TH, Jones D, **Fineman MS**, McKeown A, Leng T, Bauman CR, Hlekamp N.Ophthalmol Retina. 2024 Nov 19:S2468-6530(24)00543-8. doi: 10.1016/j.oret.2024.11.013. Online ahead of print.PMID: 39571793
9. High-dose Intravitreal Topotecan for Perifoveal Recurrence of Retinoblastoma. **Woods MM, Bansal R, Shields CL.**Ophthalmol Retina. 2024 Nov 16:S2468-6530(24)00481-0. doi: 10.1016/j.oret.2024.10.010. Online ahead of print.PMID: 39556070 No abstract available.
10. Macular chorioretinal scar as a rare complication of serous retinal detachment in retinopathy of prematurity. **Dmitriev PM**, Li Y, **Vander JF, Wasserman BN.**BMJ Case Rep. 2024 Nov 14;17(11):e255039. doi: 10.1136/bcr-2023-255039.PMID: 39542504
11. A novel 3D printing method for a notched eye plaque "dummy" for uveal melanoma brachytherapy. Mourtada F, Belko S, Monane R, Pugliese R, Komarnicky-Kocher L, **Lally SE**, Wang W, **Shields CL**, Emrich J.Brachytherapy. 2024 Nov 12:S1538-4721(24)00396-9. doi: 10.1016/j.brachy.2024.09.002. Online ahead of print.PMID: 39537436
12. A Computational Approach to Characterize the Protein S-Mer Tyrosine Kinase (PROS1-MERTK) Protein-Protein Interaction Dynamics. **Djulgovic MB**, Gonzalez DJT, Laratelli L, Antonietti M, Uversky VN, **Shields CL**, Karp CL.Cell Biochem Biophys. 2024 Nov 13. doi: 10.1007/s12013-024-01582-5. Online ahead of print.PMID: 39535659
13. Intravitreal Melphalan for Vitreous Metastases from Cutaneous Melanoma. **Cain RE, Chou YB, Shields CL.**Ophthalmology. 2024 Nov 9:S0161-6420(24)00636-5. doi: 10.1016/j.ophtha.2024.10.015. Online ahead of print.PMID: 39530956 No abstract available.
14. The Association Between Medical Insurance, Access to Care, and Outcomes for Patients with Uveal Melanoma in the United States. Marks VA, Williams BK Jr, Leapman MS, **Shields CL.**Semin Ophthalmol. 2024 Nov 9:1-12. doi: 10.1080/08820538.2024.2426479. Online ahead of print.PMID: 39520301

15. Long-Term Stability, Sterility, And Cost-Effectiveness of 0.05% Chlorhexidine Gluconate as Antisepsis for Intravitreal Injection. **Durrani AF, Momenaei B,** Soni V, Tennant M, **Hsu J, Vander J, Spirn M,** Kang EY, Hwang YS, Kaushal G, **Garg SJ.** *J Ocul Pharmacol Ther.* 2024 Nov;40(9):581-587. doi: 10.1089/jop.2024.0071. Epub 2024 Aug 22. PMID: 39169875

16. Do Treatment Patterns for Endophthalmitis after Cataract Surgery Follow the Endophthalmitis Vitrectomy Study Recommendations?: An Academy IRIS® Registry Analysis. **Tomaiuolo M, Deaner J,** VanderBeek BL, **Acharya B, Syed ZA, Zhang Q, Schuman JS, Hyman L.** *Ophthalmol Retina.* 2024 Nov;8(11):1035-1043. doi: 10.1016/j.oret.2024.07.014. Epub 2024 Jul 22. PMID: 39048058

17. Screen Failures in Clinical Trials in Retina. Hasan N, Mehrotra K, Danzig CJ, Eichenbaum DA, Ewald A, **Regillo C, Momenaei B,** Sheth VS, Lally DR, Chhablani J. *Ophthalmol Retina.* 2024 Nov;8(11):1093-1099. doi: 10.1016/j.oret.2024.05.014. Epub 2024 May 27. PMID: 38810882

18. Intraocular pressure profile following selective laser trabeculoplasty in pigmentary and primary open-angle glaucoma. **Hallaj S, Sinha S, Mehran NA, Morrill AM, Pro MJ, Dale E, Schmidt C, Kolomeyer NN, Shukla AG, Lee D, Moster MR, Myers JS, Jay Katz L, Razeghinejad R.** *Eur J Ophthalmol.* 2024 Nov;34(6):1957-1963. doi: 10.1177/11206721241237305. Epub 2024 Mar 12. PMID: 38470322

19. Systemic effects of anti-VEGF intravitreal injection in patients with age-related macular degeneration: A multi-institutional real-world study. Lin TY, Hsieh YT, **Garg SJ,** Chen LJ, Chen KJ, Wu WC, Lai CC, Hwang YS, Kang EY. *Indian J Ophthalmol.* 2024 Nov 1;72(Suppl 5):S809-S815. doi: 10.4103/IJO.IJO_3194_23. Epub 2024 Aug 14. PMID: 39141487

20. Update on "Cell Therapy" Clinics Offering Treatments of Ocular Conditions Using Direct-To-Consumer Marketing Websites in the U.S. Kalavar M, Lovett EA Jr, Nicholas MP, Ross-Hirsch A, Nirwan RS, Sridhar J, Patel S, Flynn HW Jr, Albini TA, **Kuriyan AE.** *Am J Ophthalmol.* 2024 Nov;267:135-141. doi: 10.1016/j.ajo.2024.06.014. Epub 2024 Jun 15. PMID: 38880376

21. A Detailed Analysis of Individuals Having Graft Failure After Corneal Transplantation. Duman F, Guler A, Kosker M, Azari AA, Marangoz D, **Hammersmith KM,** Nagra PK, **Rapuno CJ.** *Semin Ophthalmol.* 2024 Nov;39(8):634-638. doi: 10.1080/08820538.2024.2354693. Epub 2024 May 16. PMID: 38753532